Soligenix
29 Emmons Drive
Suite C-10
Princeton
New Jersey
08540
United States
Tel: 609-538-8200
Fax: 609-452-6467
Website: http://www.soligenix.com/
414 articles about Soligenix
-
Soligenix Announces SGX942 Receives Promising Innovative Medicine Designation From The UK Medicines And Healthcare Products Regulatory Agency
12/12/2016
-
Soligenix Announces Positive Long-Term Follow-Up Results From Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
12/8/2016
-
Soligenix Announces Recent Accomplishments And Third Quarter 2016 Financial Results Highlighted By Revenues Of $3.0 Million
11/11/2016
-
Soligenix Receives EMA Designation As Small And Medium Enterprise
10/25/2016
-
Soligenix Announces Publication Of Its Phase 2 Clinical Trial Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
10/18/2016
-
Soligenix To Receive $530,000 In Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
10/17/2016
-
Soligenix Announces Poster Presentations From Its Gastrointestinal Acute Radiation Syndrome Program At The 2016 Radiation Research Society Meeting
10/13/2016
-
Soligenix Announces Poster Presentation Of Its Ricin Vaccine And Dusquetide Orphan Programs At The 2016 NORD Rare Diseases And Orphan Products Breakthrough Summit
10/11/2016
-
Soligenix Announces Reverse-Split In Preparation For Proposed Up-Listing Of Its Common Stock To The NASDAQ Capital Market
10/7/2016
-
Soligenix To Present At 2016 Aegis Growth Conference
9/15/2016
-
Soligenix And SciClone Establish Regional Licensing Agreement For SGX942, A Novel Product Candidate For Oral Mucositis
9/12/2016
-
Soligenix Announces Issuance Of New Composition Of Matter Patent For Dusquetide Analogs
9/6/2016
-
FDA Grants Soligenix Orphan Drug Designation For Dusquetide For Treatment Of Macrophage Activation Syndrome
8/18/2016
-
Soligenix Announces Recent Accomplishments And Second Quarter 2016 Financial Results Highlighted By Revenues Of $3.2 Million
8/11/2016
-
Soligenix Receives Additional BARDA And NIAID Funding To Advance Development Of OrbeShield In GI ARS
7/25/2016
-
Soligenix Announces Presentation Of Positive Preliminary Results Of A Heat Stable Ebola Vaccine Formulation
7/18/2016
-
Soligenix Taps a New CFO
6/20/2016
-
Soligenix Announces Presentation Of Phase 2 Oral Mucositis Clinical Trial Results At The 2016 Multinational Association For Supportive Care In Cancer Conference
6/6/2016
-
Soligenix Release: FDA Grants Soligenix "Fast Track" Designation For SGX943 For The Treatment Of Melioidosis
5/31/2016
-
Soligenix To Present At The 2016 Marcum MicroCap Conference
5/26/2016